TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

MATULANE

PROCARBAZINE HYDROCHLORIDE
Oncology Approved 1969-07-22
1
Indication
--
Phase 3 Trials
1
Priority Reviews
56
Years on Market

Details

Status
Prescription
First Approved
1969-07-22
Routes
ORAL
Dosage Forms
CAPSULE

Companies

Active Ingredient: PROCARBAZINE HYDROCHLORIDE

MATULANE Approval History

Loading approval history...

What MATULANE Treats

1 indications

MATULANE is approved for 1 conditions since its original approval in 1969. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hodgkin's Disease
Source: FDA Label

MATULANE Boxed Warning

WARNING It is recommended that MATULANE be given only by or under the supervision of a physician experienced in the use of potent antineoplastic drugs. Adequate clinical and laboratory facilities should be available to patients for proper monitoring of treatment....

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

MATULANE FDA Label Details

Pro

Indications & Usage

Matulane is indicated for use in combination with other anticancer drugs for the treatment of Stage III and IV Hodgkin's disease. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen.

โš ๏ธ BOXED WARNING

WARNING It is recommended that MATULANE be given only by or under the supervision of a physician experienced in the use of potent antineoplastic drugs. Adequate clinical and laboratory facilities should be available to patients for proper monitoring of treatment....

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.